Table of Contents Table of Contents
Previous Page  200 / 916 Next Page
Show Menu
Previous Page 200 / 916 Next Page
Page Background


25th European Congress of Psychiatry / European Psychiatry 41S (2017) S170–S237


EPSmay influence functional remission at several lev-

els starting from the neurobiological to the social stigmatization

and the treatment adherence levels. Further research in this matter

is required.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Concomitant psychotropic

medications and functional remission

in schizophrenia patients

B. Ghajati

1 ,

, C. Leila


, L. Raja


, C. Majda



Razi Hospital, Psychiatry Department “C”, Tunis, Tunisia


Razi Hospital, Psychiatry Department “E”, Tunis, Tunisia

Corresponding author.

Along with the rise of symptomatic and functional remission

concepts in schizophrenia, multiple aspects of the disease treat-

ment have been explored in their link to vocational prognosis.

Although antipsychotics are the corner stone treatment, monother-

apy is seldom. In fact, concomitant psychotropicmedications (CPM)

use during treatment of schizophrenia has dramatically increased



To examinewhether concomitant psychotropicmedications

use is associated to functional remission in schizophrenia patients.


A cross-sectional, retrospective and descriptive study

was conducted in the psychiatry department “C”, in Razi hospi-

tal (Tunis), between October 2014 and March 2015. Sixty patients

suffering from schizophrenia spectrum disorder (DSM IV-R) were

included. Functional status was explored with the Global Assess-

ment of Functioning Scale (GAF), the Social and Occupational

Functioning Assessment scale and the Social Autonomy Scale (EAS).

Sociodemographic and therapeutic characteristics have been col-

lected during a semi-structured interview.


Rates of functional remission were respectively: 63.30%

at theGAF scale, 48.30% at the SOFAS and51.70% at the SAS. Antipsy-

chotics were prescribed alone in more than half patients (56.70%),

mood stabilizers in 40% and antidepressants in 1.7% of the cases.

Benzodiazepines were prescribed in 40% of the patients. There was

no association between CPM use and functional remission, using

three scales (GAF:


= 0.091; SOFAS = 0.125; EAS = 0.728).


Largely used, concomitant psychotropic medica-

tions can increase side effects, cause drug interactions, escalate

treatment costs, and lead to non-adherence. That is said, their ther-

apeutic effectiveness should be thoroughly investigated, aiming to

recovery not only symptoms control.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Functional connectivity of the ventral

tegmental area and avolition in

schizophrenia: A resting state

functional MRI study

G.M. Giordano

1 ,

, M .


2 , A. M


1 , M.


2 ,

S. Galderisi



University of Naples SUN, Department of Psychiatry, Largo

Madonna delle Grazie, 80138, Napoli, Italy


University of Naples SUN, Laboratory of Neuronal Networks,

Department of Mental and Physical Health and Preventive Medicine,

Via Luciano Armanni 5, 80138, Napoli, Italy

Corresponding author.


Impaired motivation is considered a fundamental

aspect of the Avolition domain of negative symptoms. The ventral

tegmental area (VTA) contains the highest number of DA neurons

projecting to the brain areas involved in motivation-related pro-



The aimof our studywas to investigate by functionalMRI the

resting-state functional connectivity (RS-FC) of the VTA in patients

with schizophrenia and its relationships with real-life motivation

and avolition.


The RS-FC was investigated in 22 healthy controls (HC)

and in 26 schizophrenia patients (SCZ) treated with second gen-

eration antipsychotics only and divided in high (HA = 13) and low

avolition (LA = 13) subgroups. We used the Quality of Life Scale and

the Schedule for the Deficit Syndrome to assess real-life motivation

and avolition, respectively.


HA, as compared to LA andHC, showed a reduced RS-FC of

VTA with the right ventrolateral prefrontal cortex (R VLPFC), right

posterior insula (R pINS) and right lateral occipital cortex (R LOC).

The RS-FC for these regions was positively correlated with motiva-

tion in the whole sample and negatively correlated with avolition

in schizophrenia patients.


Our findings demonstrate that motivational deficits

in schizophrenia patients are linked to reduced functional connec-

tivity in the DA circuit involved in retrieval of the outcome values of

different actions to guide behavior. Further characterization of the

factors modulating the functional connectivity in this circuit might

foster the development of innovative treatments for avolition.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


The impact of cannabis in the early

stages of schizophrenia: A 3-year

longitudinal study on cannabis

influence on relapse rates

M. Gomez Revuelta

1 ,

, M .

Juncal Ruiz

2 , O.

Porta Olivares

2 ,

V. Gajardo Galan

2 , G.

Pardo de Santayana Jenaro

2 ,

L. Sanchez Blanco

2 , D.

Abejas Diez

2 , R. L

andera Rodriguez

2 ,

L. Garcia Ayal

a 2 , N.I

. Nu˜nez Morales

2 , M.

Fernandez Rodriguez



Hospital Universitario de Álava-Sede Santiago, Vitoria, Gasteiz,

Psychiatry, La Penilla, Spain


Hospital Universitario Marques de Valdecilla, Psychiatry,

Santander, Spain

Corresponding author.


The first five years after the onset of a first episode

of psychosis (FEP) are crucial for long term outcome. In this period,

the risk of relapse is particularly high. Consequences of relapse

include an increased risk of neurotoxicity, chronicity, hospitaliza-

tion, decreased response to treatment, increased economic burden

and functional impairment.


To discern the influence of cannabis on relapse as it

may contribute to adopt specific measures in patients during early

stages of the illness.

Material and methods

PAFIP is an early intervention program for

patients with a FEP. Between January 2005 and January 2011, 163

patients were recruited for this study. They were followed-up dur-

ing 3 years at intervals of three months. The sample was divided

into three groups: (1) those non-cannabis users neither before the

FEP nor during follow-up (nn), (2) consumers before the FEP and

during follow-up (ss) and (3) consumers before the FEP that gave

up consumption during follow-up (sn).


No statistically significant differences between the three

groupswere observed but a trend (


= 0.057) towards amore endur-

ing survival in Group 3 (sn). (Kaplan–Meier curve and detailed Log

Rank Test results will be included in the final poster).


Cannabis has a detrimental effect on schizophrenia.

The interruption of its use could contribute to improve the outcome

of the disease, as the results of our study suggest.